# Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

> **NCT05054114** · NA · COMPLETED · sponsor: **SPP Pharmaclon Ltd.** · enrollment: 630 (actual)

## Conditions studied

- COVID-19 Respiratory Infection
- Acute Respiratory Disease

## Interventions

- **DRUG:** Interferon gamma human recombinant (IFN-G)

## Key facts

- **NCT ID:** NCT05054114
- **Lead sponsor:** SPP Pharmaclon Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-21
- **Primary completion:** 2021-05-25
- **Final completion:** 2021-09-02
- **Target enrollment:** 630 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054114, "Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05054114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*